Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$834,448.00
Summary
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.
Structural Basis For Helicobacter Pylori Adhesion To Host Epithelial Cells
Funder
National Health and Medical Research Council
Funding Amount
$665,328.00
Summary
The aim of this grant is to understand how the bacteria that cause gastric cancer and ulcers interact with the cells that line the stomach. This information will be used to develop new treatments to combat disease.
Acid Resistance Mechanisms Of Helicobacter Pylori And Their Impact On Gastric Colonisation
Funder
National Health and Medical Research Council
Funding Amount
$287,036.00
Summary
The gastric bacterium, Helicobacter pylori, infects more than half the population of the globe. H. pylori may cause either no symptomatic disease, induce peptic ulcers or be responsible for one of the major killing cancers, gastric cancer. Millions die or suffer from this infection each year. Yet we are remarkably ignorant of why the infection causes these different patterns of disease. This project aims to provide evidence to show that the very mechanism the bacterium has acquired to help it re ....The gastric bacterium, Helicobacter pylori, infects more than half the population of the globe. H. pylori may cause either no symptomatic disease, induce peptic ulcers or be responsible for one of the major killing cancers, gastric cancer. Millions die or suffer from this infection each year. Yet we are remarkably ignorant of why the infection causes these different patterns of disease. This project aims to provide evidence to show that the very mechanism the bacterium has acquired to help it resist stomach acid and so live in the stomach, is responsible for these differences. I.e. The organism lives in different parts of the stomach due to differences in local acid at that site. If the acid in a particular part of the stomach is too high, the acid resistance mechanism cannot cope. If the acid is too low, the organism also cannot grow well. Because the bacterium has evolved to only thrive in a relatively narrow range of acid, it will behave very differently in these different parts of the stomach. This results in different diseases. Various populations in different countries of the world have different levels of acid production and this also explains why in some countries duodenal ulcers predominate and in others gastric ulcer- gastric cancer is the norm. Showing why H. pylori lives where it lives will provide fundamental information relevant to understanding some of the world s major diseases and will also provides insights relevant to the design of new therapeutic approaches.Read moreRead less
Toll-like Receptor 2 Signalling As A Potential Therapeutic Target In Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$323,091.00
Summary
Stomach cancer is the fourth most deadly cancer in the world. Stomach cancer is closely linked with inflammation, and we have shown that a key inflammatory molecule, called toll-like receptor 2 (TLR2), can drive the development of stomach cancer. However, this occurs in a non-inflammatory manner. My research aims to understand how TLR2 is involved in the progression of stomach cancer, with the ultimate goal to find an early biomarker of disease, and to develop better therapies.
Understanding the mechanisms in the development of mutations in cancers will assist in development of targeted therapies to overcome chemotherapy resistance. The recently discovered TMPRSS2:ERG fusion in prostate cancer is unique as dominant fusion translocations are uncommon in solid organ malignancy. Activation induced cytidine deaminase (AID) is thought to play a role. Understanding the role of AID and downstream DNA repair pathways may be a target for future therapies in cancer.
Role Of Gastrin Prohormones In The Development Of Gastrointestinal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$612,885.00
Summary
Gastrin is a stomach hormone which increases acid secretion and the growth of the stomach and bowel. This growth promoting effect may be involved in a number of cancers particularly colon cancer. The different types of gastrin have different effects but we do not know which forms are important and whether all are active. The types and activity of different gastrins will be investigated using cell lines, animal models and colon cancer patients with the view of establishing new treatments.
Molecular Markers Of The Progression Of Intestinal Metaplasia To Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$556,618.00
Summary
Gastric cancer (GC) is the second most common cause of cancer-related death globally. It is a surgically treatable disease that has good prognosis if detected at an early stage. The majority of patients in our community are detected at a late stage, where less than 20% of patients survive 5 years. The majority of GC is preceded by distinct histological stages that follow a progression from gastric mucosal inflammation, intestinal metaplasia (IM) and eventually cancer. These stages are characteri ....Gastric cancer (GC) is the second most common cause of cancer-related death globally. It is a surgically treatable disease that has good prognosis if detected at an early stage. The majority of patients in our community are detected at a late stage, where less than 20% of patients survive 5 years. The majority of GC is preceded by distinct histological stages that follow a progression from gastric mucosal inflammation, intestinal metaplasia (IM) and eventually cancer. These stages are characterised by genetic events that are largely unknown and occur over a period that can take years. It is also evident, especially in countries where GC is not as prevalent, that only a proportion of individuals will eventually develop GC. The long latency from the develpoment of IM and diagnosis of GC offers an opportunity to intervene and study the changes that lead to GC as well as find genes that may predict which individuals will progress. IM is the stage in which intervention is obvious. It is very easily diagnosed, is present for a long time and, for certain individuals, will eventually accumulate enough genetic events that will mandate progression to GC. Targeted screening of these individuals will enable a feasible strategy to find early GC, and avoid costly non-targeted screening. This proposal seeks to find key genetic events responsible for the transition of IM to GC. The first step utilises Affymetrix arrays to detect genes expressed in IM and specifically linked to GC. These candidates will be validated and used to study their role in the progression to GC using a mouse model of GC. This study is designed to find genes responsible for GC that can be used as: 1) a marker of progression in humans that will be used as a tool to stratify individuals into a screening protocol; 2) candidates to be tested in animal studies to study the pathogenesis of GC and potentially used as preventative or therapeutic targets.Read moreRead less
Helicobacter Pylori VacA Toxin: Modulation Of Human Mitochondrial Function By A Bacterial Pathogen
Funder
National Health and Medical Research Council
Funding Amount
$508,003.00
Summary
This work will greatly further our understanding of how a bacterium, Helicobacter pylori, causes stomach ulcers and cancer. We will use cutting edge model systems to study the VacA toxin that is secreted from the bacteria and is targeted to human cells. We will examine where the toxin goes and how it affects our cells. It is expected that the improved understanding that will arise from this work will assist researchers to better devise drugs against this prevalent pathogen.
Fzd receptors are often upregulated in gastric cancer, and recent studies have shown that targeting these receptors has be effective at reducing cancer cell growth in other cancers including prostate and breast. This project will use cutting edge technology to firstly determine the specific requirement for Fzd receptors during gastric cancer and then determine the therapeutic benefit of using an antibody to target these receptors in mouse models and human gastric cancer cells.